| Patients with a confirmed SARS-CoV-2 infection, n = 39 | Non-infected patients n = 457 | p |
---|---|---|---|
Age (years), median [IQR25-75] | 56.9 (47.6–65.9) | 56.9 (43.5–67.2) | 0.80 |
Female, n (%) | 29 (74.4%) | 363 (79.4%) | 0.42 |
Preventive work cessation, n (%) | 3 (9.1%) | 49 (11.8%) | 0.64 |
At least one contact with a confirmed COVID-19 case, n (%) | 16 (42.1%) | 27 (5.9%) | < 0.0001 |
Self-suspected SARS-CoV-2 infection (n = 201) (according to the patient him/herself), n (%) | 32 (84.2%) | 122 (26.8%) | < 0.0001 |
Risk factors for SARS-CoV-2 infection (history of), n (%)[1054] | Â | Â | Â |
 Cancer | 2 (7.9%) | 25 (5.5%) | 0.53 |
 Cardiac failure | 1 (2.6%) | 14 (3.1%) | 0.88 |
 Myocardial infarction | 0 | 15 (3.3%) | 0.26 |
 Diabetes | 1 (2.6%) | 30 (6.6%) | 0.34 |
 Hypertension | 9 (23.7%) | 126 (27.6%) | 0.61 |
 Cerebrovascular event | 3 (7.9%) | 24 (5.3%) | 0.49 |
 Respiratory failure | 5 (13.2%) | 70 (15.3%) | 0.72 |
 Renal failure | 2 (5.3%) | 36 (7.9%) | 0.56 |
 Hepatic insufficiency | 2 (5.3%) | 20 (4.4%) | 0.80 |
BMI (kg/m2), median [IQR25-75] | 24.2 (21.3–28.2) | 24.8 (21.5–28.7) | 0.36 |
 BMI > 35 | 2 (5.4%) | 31 (7.7%) | 0.62 |
 BMI > 40 | 0 | 13 (3.2%) | 0.27 |
Smoking status, n (%) | Â | Â | 0.13 |
 Current smoker | 1 (2.8%) | 65 (15.0%) |  |
 Former smoker | 13 (36.1%) | 141 (32.5%) |  |
 Never smoker | 22 (61.1%) | 228 (52.5%) |  |
 Smoking ever | 14 (38.9%) | 206 (47.5%) | 0.32 |
Treatments, n (%)[1054] | Â | Â | Â |
 NSAIDs | 5 (13.2%) | 28 (6.1%) | 0.09 |
 Glucocorticoids | 9 (23.7%) | 135 (29.6%) | 0.44 |
 Antimalarials (HCQ/CQ) | 14 (36.8%) | 131 (28.7%) | 0.29 |
 Immunosuppressive agents/biologics | 15 (39.5%) | 195 (42.6%) | 0.70 |
Treatment modification due to pandemic, n (%) | 10 (26.3%) | 32 (7.0%) | < 0.0001 |
Reporting a flare-up of AISD (self-diagnosed), n (%) | 13 (34.2%) | 58 (12.7%) | 0.0003 |
Serological status for SARS-CoV-2, n (%) | Â | Â | Â |
 Positive IgG and/or IgM | 31/33 (93.9%) | 0 | < 0.0001 |